Regeneron Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.05.23	Regeneron Pharmaceuticals Q1 Profit Decreases, but beats estimates (RTTNews)
28.03.23	Regeneron Partners With Sonoma Biotherapeutics To Develop T Cell Therapies (RTTNews)
22.03.23	Regeneron : FDA Approves Evkeeza To Treat Ultra-rare Form Of High Cholesterol In Young Children (RTTNews)
21.03.23	Sanofi : EU Approves Dupixent To Treat Severe Atopic Dermatitis In Children (RTTNews)
15.03.23	Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease (PR Newswire)
06.03.23	Roche Announces FDA Approval Of Label Expansion For VENTANA PD-L1 Assay (RTTNews)
01.03.23	FDA Approves Regeneron's Kevzara To Treat Inflammatory Rheumatic Disease (RTTNews)
28.02.23	Biotech Stocks Facing FDA Decision In March 2023 (RTTNews)
21.02.23	Regeneron Pharma: FDA Accepts For Priority Review BLA For Pozelimab (RTTNews)
03.02.23	Regeneron Pharma Q4 Profit Declines; Adj. Total Revenues Up 14% (RTTNews)
03.02.23	Regeneron Pharmaceuticals Q4 Profit Declines (RTTNews)
29.01.23	Biotech Stocks Facing FDA Decision In February 2023 (RTTNews)
27.01.23	Regeneron Pharma: CHMP Adopts Positive Opinion For Dupixent (RTTNews)
24.01.23	Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math Competition (PR Newswire)
05.01.23	Sensei Biotherapeutics Enters Clinical Supply Agreement With Regeneron For Libtayo (RTTNews)
23.12.22	Regeneron Granted Marketing Authorization For Libtayo In Japan For Recurrent Cervical Cancer (RTTNews)
23.12.22	Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer (PR Newswire)
22.12.22	Regeneron : Positive Dupixent Phase 3 Results In Eosinophilic Esophagitis Published (RTTNews)
21.12.22	Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine (PR Newswire)
19.12.22	Regeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire)
16.12.22	Regeneron: CHMP Recommends Dupixent For EU Approval To Treat Eosinophilic Esophagitis (RTTNews)
16.12.22	Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis (PR Newswire)
15.12.22	Regeneron, Sanofi: Dupixent Approved In EU For Prurigo Nodularis (RTTNews)
15.12.22	Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis (PR Newswire)
12.12.22	Odronextamab (CD20xCD3) Demonstrates High and Durable Complete Response Rate among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 Trial (PR Newswire)
12.12.22	Regeneron Pharma Announces Positive Data From Mid-stage Study Of Linvoseltamab (RTTNews)
12.12.22	Linvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple Myeloma (PR Newswire)
12.12.22	Regeneron Named on Dow Jones Sustainability World Index for Fourth Consecutive Year (PR Newswire)
11.12.22	Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH (PR Newswire)
01.12.22	Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (cemiplimab) in Multiple Solid Tumor Types (PR Newswire)
30.11.22	Regeneron Pharma: Evkeeza SBLA Granted FDA Priority Review (RTTNews)
30.11.22	Evkeeza® (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Priority Review (PR Newswire)
25.11.22	Form 4 872589 (RSS)
22.11.22	Regeneron :EC Oks Libtayo As First Immunotherapy In Second Line Recurrent/Metastatic Cervical Cancer (RTTNews)
22.11.22	Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology (PR Newswire)
17.11.22	Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer (PR Newswire)
11.11.22	Regeneron, Sanofi: CHMP Recommends Approval Of Dupixent In The EU (RTTNews)
11.11.22	Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis (PR Newswire)
10.11.22	Form 4 872589 (RSS)
08.11.22	Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC) (PR Newswire)
05.11.22	Aflibercept 8 mg Late-breaking Data Presented at Retina Society in Diabetic Macular Edema and Wet Age-related Macular Degeneration (PR Newswire)
03.11.22	Regeneron Announces Investor Conference Presentations (PR Newswire)
03.11.22	Regeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and Disorders (PR Newswire)
03.11.22	Regeneron Pharmaceuticals Q3 Profit Decreases, but beats estimates (RTTNews)
03.11.22	Regeneron Reports Third Quarter 2022 Financial and Operating Results (PR Newswire)
03.11.22	Form 8-K 872589 (RSS)
03.11.22	Form 10-Q 872589 (RSS)
02.11.22	Form 4 872589 (RSS)
28.10.22	Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) Wins Prestigious 2022 Prix Galien USA Best Biotechnology Product Award (PR Newswire)
21.10.22	Regeneron: FDA Grants Pediatric Exclusivity For EYLEA (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

17.12.24		Schwacher Wochentag in New York: NASDAQ 100 verbucht letztendlich Abschläge
17.12.24		Minuszeichen in New York: NASDAQ 100 verliert nachmittags
17.12.24		Zurückhaltung in New York: NASDAQ 100 präsentiert sich schwächer
12.12.24		Schwache Performance in New York: NASDAQ 100 zeigt sich schlussendlich schwächer
12.12.24		Angespannte Stimmung in New York: NASDAQ 100 präsentiert sich schwächer
12.12.24		Schwacher Handel: NASDAQ 100 am Mittag in der Verlustzone
05.12.24		Börse New York in Rot: NASDAQ 100 zum Ende des Donnerstagshandels schwächer
19.11.24		Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen

17.12.24

Schwacher Wochentag in New York: NASDAQ 100 verbucht letztendlich Abschläge

17.12.24

Minuszeichen in New York: NASDAQ 100 verliert nachmittags

17.12.24

Zurückhaltung in New York: NASDAQ 100 präsentiert sich schwächer

12.12.24

Schwache Performance in New York: NASDAQ 100 zeigt sich schlussendlich schwächer

12.12.24

Angespannte Stimmung in New York: NASDAQ 100 präsentiert sich schwächer

12.12.24

Schwacher Handel: NASDAQ 100 am Mittag in der Verlustzone

05.12.24

Börse New York in Rot: NASDAQ 100 zum Ende des Donnerstagshandels schwächer

19.11.24

Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

CieFinRichemont	137.35	1.40 %	K V
Sonova Hldg	297.30	1.29 %	K V
Logitech Intl	74.86	1.22 %	K V
Nestle	75.22	1.02 %	K V
Alcon	76.32	0.95 %	K V
UBS Group	28.17	-0.67 %	K V
Swiss Re	131.95	-0.68 %	K V
Geberit	533.80	-0.78 %	K V
Lonza Grp	541.40	-0.81 %	K V
Kuehne+Nagel Int	202.60	-1.65 %	K V

Nachrichten zu Regeneron Pharmaceuticals Inc.

Aktien Top/Flop

Regeneron Pharmaceuticals Peer Group Nachrichten

Meistgelesene Nachrichten